Cancer Cachexia Market Size & Share, by Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids); Mode of Action (Weight Loss Stabilizers, Appetite Stimulants); Indication (Cancer, CHF, Rheumatoid Arthritis, Chronic Kidney Disease, Cystic Fibrosis, COPD); Route Of Administration (Oral, Parenteral); Dosage Form (Tablets, Injections); Distribution Channel (Hospital, Retail & Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5372
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2036

Cancer Cachexia Market size is expected to cross USD 4.5 Billion by the end of 2036, growing at a CAGR of 4.5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of cancer cachexia was over USD 2.6 Billion. Over the course of the projection period, which runs from 2024 to 2036, the growing geriatric population is anticipated to support market expansion. The percentage of the population that is 60 years of age or older is rising. There were one billion individuals sixty years of age or older in the world in 2019. By 2030, there will be 1.4 billion, and by 2050, there will be 2.1 billion. Elderly people's weakened immune systems make them more prone to diseases, which is predicted to accelerate the market's growth pace.

In addition to these, the market for cancer cachexia will also grow as a result of increased awareness-raising campaigns by public and private institutions. The market for cancer cachexia will also grow as a result of developments in the treatment of cancer cachexia and sedentary lifestyles.

/admin/upload_images/Cancer Cachexia Market.webp
Get more information on this report: Request Free Sample PDF

Cancer Cachexia Market: Key Insights

Base Year


Forecast Year



~ 4.5%

Base Year Market Size (2023)

 ~ USD 2.6 Billion

Forecast Year Market Size (2036)

 ~ USD 4.5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Cancer Cachexia Sector: Growth Drivers and Challenges


Growth Drivers

  • The Incidence of Chronic Illnesses is Rising- The market for cancer cachexia is expected to rise as chronic diseases including diabetes, cancer, heart failure, and others become more common. Heart failure (HF) affects about 6.7 million adults over the age of 20, and by 2030, that number is predicted to increase to 8.5 million. The lifetime risk of heart failure has risen to 24%; almost 1 in 4 people will get heart failure at some point in their lives. The market for cancer cachexia will grow as a result of the increased prevalence of cancer cachexia and the development of cutting-edge therapeutics to address it.
  • Infrastructure Spending in the Healthcare Sector is Increasing- The market for cancer cachexia is also growing at a large rate due to increased healthcare spending, which supports the development of the industry's infrastructure. Additionally, by boosting funding, a number of government organizations hope to strengthen the healthcare infrastructure, which would further alter the dynamics of the market. The amount spent on Medicare increased by 8.4% to USD 900.8 billion in 2021, or 21% of the entire NHE. Medicaid spending increased to USD 734.0 billion in 2021, or 17.5% of the entire NHE, a 9.2% increase. In 2021, the amount spent on private health insurance increased by 5.8% to USD 1,211.4 billion, or 28% of the total NHE.
  • Robust R&D and Pipeline for Products- Due to the high prevalence of cachexia instances among cancer patients worldwide, clinical research aimed at defining the features of cancer cachexia in a variety of human cancer types has received more attention. It is critical to comprehend the molecular pathways underlying muscle loss as cancer cachexia advances in order to enhance cancer outcomes. Furthermore, a surge in research and development efforts is driving the market's expansion. This will present advantageous prospects for the market expansion of cancer cachexia. In addition to these, an increase in drug launches and approvals will accelerate the market's growth rate.


  • Tight Regulating Guidelines- Since cancer cachexia is more common among cancer patients who are nearing the end of their lives, medications used to treat this condition typically have to closely follow the guidelines set by other medications used to treat cancer. Due to strict regulatory standards, several nations have lengthy approval processes for pharmaceuticals, particularly those connected to cancer. The amount of time needed for cancer medications to be approved by each country varies greatly depending on the current national regulatory norms. For instance, the FDA in the US is required to decide on standard applications within 12 months and on applications designated for priority review within 6 months.
  • The high expense of the treatment will hinder the market's rate of growth.
  • The market for cancer cachexia will face challenges due to the shortage of qualified practitioners in developing nations.

Cancer Cachexia Segmentation

Mode of Action (Weight Loss Stabilizers, Appetite Stimulants)

The weight loss stabilizers segment in the cancer cachexia market is anticipated to hold the largest share of about 55% during the forecast period. Because cancer patients experience extreme weight loss, weight loss stabilizers dominate the market for cancer cachexia. Physicians offer weight loss stabilizers to counteract weight loss and improve the quality of life for cancer patients experiencing cachexia. Cytokine inflammation, tissue loss, wasting syndrome, and cystic fibrosis are the hallmarks of cachexia. To enhance the quality of life for cancer patients, it is imperative to counteract weight loss in this condition. Cachexia results from uncontrollably losing muscle mass, dying from radiation and chemotherapy, and seeing an 85% increase in the last one to two weeks. Furthermore, as the condition progresses, 45% of patients lose more than 10% of their initial weight. Weight stabilizers are advised by doctors to prevent cachexia.

Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids)

The progestogens segment is expected to hold 48% share of the cancer cachexia market by 2036. The primary reasons for this are progestogen's cost-effectiveness, tolerability, and efficacy in treating cachexia. Since progestogens are more effective than other medications, it is anticipated that demand for them will stay high over the coming years. In addition to these, the most efficient and painless treatment for cancer cachexia was progestogens. As a result, it will still be significant in the progestogens market sector. The goals of the current treatments are cancer cachexia palliation as well as patient and family relief.

Our in-depth analysis of the global cancer cachexia market includes the following segments:


  • Progestogens
  • Dronabinol
  • Mega Sterol Acetate
  • Corticosteroids

          Mode of Action

  • Weight Loss Stabilizers
  • Appetite Stimulants


  • Cancer
  • Congestive Heart Failure (CHF)
  • Rheumatoid Arthritis
  • Chronic Kidney Disease
  • Cystic Fibrosis
  • Chronic Obstructive Pulmonary Disease (COPD)

          Route of Administration

  • Oral
  • Parenteral

          Dosage Form

  • Tablets
  • Injections


  • Hospitals
  • Specialty Clinics
  • Homecare

          Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cancer Cachexia Industry - Regional Synopsis

North America Market Forecast

North America cancer cachexia market is expected to hold largest revenue share of about 30% during the forecast period. The market for cancer cachexia is dominated by North America due to the region's rising prevalence of chronic illnesses like cancer and expanding knowledge of cachexia treatments. The availability of treatment choices and growing healthcare costs will also accelerate the market's development pace in this region. North America is anticipated to lead the market because of the region's high cancer and cancer cachexia rates, abundance of pharmaceutical companies, and evolving approaches to cancer patient treatment. Mexico is estimated to have about 195,499 new cases of cancer, based on a survey in 2020. In addition, the American Cancer Society 2022 projects that there will be 1.9 million new cancer diagnoses in the US in 2022.

APAC Market Statistics

Cancer cachexia market in the Asia Pacific is predicted to account for 27% of the revenue share by the end of 2036. The growth of the market is because this area is home to generic producers. Additionally, the expansion of government initiatives and the construction of healthcare infrastructure will accelerate the growth rate of this market in this region.

Research Nester
/admin/upload_images/Cancer Cachexia Market Size.webp
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cancer Cachexia Market

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Veru Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Mylan N.V.
    • ANI Pharmaceuticals
    • Novartis AG
    • Hikma Pharmaceuticals Plc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.


In The News

  • Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of enobosarm, Veru’s oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor (AR), a tumor suppressor, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
  • Bristol-Myers Squibb Company successfully acquired Celgene Corporation to create a strong biopharma company. As per the officials of Bristol, its expertise in the fields of cardiovascular disease, hematology, immunology, and oncology would aid in transforming the lives of the patients through technological advancements.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5372
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of chronic diseases, drug launches, research and development are the major factors driving the growth of the cancer cachexia market.

The market size of cancer cachexia is anticipated to attain a CAGR of 4.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Veru, Inc, Eli Lilly and company, Bristol-Myers Squibb Company, Mylan N.V., ANI Pharmaceuticals, Novartis AG, Hikma Pharmaceuticals Plc., Sun pharmaceutical Industries Ltd., and others.

The weight loss stabilizers segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Cancer Cachexia Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying